Graphite Bio leads this week’s IPO squad, looking to turn the tide on sickle cell disease with gene editing

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.

Biotech’s IPO march continued earlier this week with Monte Rosa pricing on Thursday, and now Friday’s bunch heads to Nasdaq led by gene editing player Graphite Bio.

Located in South San Francisco,...

Click to view original post